ArticlesComparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis
Introduction
In the past 20 years, several new drugs have been introduced for the treatment of depression, many of which are structurally related and share similar putative mechanisms of action. As with statins for the prevention of coronary events,1 the extent to which these agents vary in terms of efficacy and acceptability is unclear. Moreover, some of the new drugs are so-called me-too drugs2—ie, chemically similar to existing drugs with expiring patents rather than genuine advances in treatment. Systematic reviews have already highlighted some differences in efficacy between second-generation antidepressants.3, 4, 5, 6, 7, 8, 9
We report an overview of all randomised controlled trials that compared 12 new-generation antidepressants in terms of efficacy and acceptability in the acute-phase treatment of major depression. We used multiple-treatments meta-analysis,10 also known as mixed-treatment comparisons meta-analysis or network meta-analysis, which allows the integration of data from direct (when treatments are compared within a randomised trial) and indirect comparisons (when treatments are compared between trials by combining results on how effective they are compared with a common comparator treatment).11 We aimed to provide a clinically useful summary of the results of the multiple-treatments meta-analysis that can be used to guide treatment decisions.
Section snippets
Study selection and data collection
At the beginning of this project, we drafted a study protocol and subsequently made it freely available to the public on our institutional website before carrying out the final analyses. Furthermore, with the publication of this paper the overall data set will be in the public domain.
For our analysis, we included only randomised controlled trials that compared any of the following 12 new-generation antidepressants (bupropion, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine,
Results
The electronic searches yielded 345 potentially relevant studies, of which 274 potentially eligible articles were analysed. We excluded 172 reports that did not meet eligibility criteria (figure 1). We identified a further 15 unpublished trials eligible for our meta-analysis from pharmaceutical industry websites. Overall, we used 117 trials from 1991 to 2007 for the multiple-treatments meta-analysis.21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44,
Discussion
Our analysis was based on 117 studies including 25 928 individuals randomly assigned to 12 different new-generation antidepressants. Our findings might help to choose among new-generation antidepressants for acute treatment of major depression. Some antidepressants differed both statistically and clinically. In terms of response, mirtazapine, escitalopram, venlafaxine, and sertraline were more efficacious than duloxetine, fluoxetine, fluvoxamine, paroxetine, and reboxetine. In terms of
References (151)
- et al.
Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents
Biol Psychiatry
(2007) - et al.
Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs
Biol Psychiatry
(2008) - et al.
Meta-analysis in clinical trials
Control Clin Trials
(1986) - et al.
Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine
J Affect Disord
(2006) - et al.
A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder
J Affect Disord
(1999) - et al.
A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine
Clin Ther
(2001) - et al.
A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline
Clin Ther
(1999) - et al.
Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial
Eur Neuropsychopharmacol
(2004) - et al.
A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients
Clin Ther
(1998) - et al.
Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression
J Affect Disord
(2000)
Escitalopram in the treatment of depressed elderly patients
Am J Geriatr Psychiatry
A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients
J Psychiatr Res
Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial
Eur Psychiatry
A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (xr) and fluoxetine for the treatment of depression
J Affect Disord
Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients
Am J Geriatr Psychiatry
A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression
Am J Geriatr Psychiatry
A systematic review and economic evaluation of statins for the prevention of coronary events
Health Technol Assess
Depression: management of depression in primary and secondary care. London: National Institute for Clinical Excellence
Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability
Intern Clin Psychopharmacol
Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis
Br J Psychiatry
Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder
Ann Intern Med
Are all antidepressants really the same? The case of fluoxetine: a systematic review
J Clin Psychiatry
Comparative effectiveness of second-generation antidepressants in the pharmacologic treatment of adult depression. Comparative effectiveness review no 7
Evaluation of networks of randomized trials
Stat Methods Med Res
Bayesian methods for evidence synthesis in cost-effectiveness analysis
Pharmacoeconomics
Antenatal and postnatal mental health. The NICE guideline on clinical management and service guidance
World Federation of Societies Biological Psychiatry Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders. Part 1: acute and continuation treatment of major depressive disorder
World J Biol Psychiatry
Interpreting treatment effects in randomised trials
BMJ
Imputing response rates from means and standard deviations in meta-analysis
Int Clin Psychopharm
What is a risk ratio?
Epidemiol Psichiatr Soc
Measuring inconsistency in meta-analyses
BMJ
Sifting the evidence—what's wrong with significance tests?
BMJ
Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy
J Clin Psychopharm
Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression
Int Clin Psychopharm
Comparison of venlafaxine XR and reboxetine in terms of efficacy and safety in major depressive disorder
Yeni Symposium
Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram
Int J Geriatr Psychiatry
Efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression
Prim Care Psychiatry
Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial
J Clin Pharm Ther
Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression
J Clin Psychopharm
Controlled comparison of paroxetine and fluvoxamine in major depression
Hum Psychopharm
Controlled comparison of milnacipran and fluoxetine in major depression
Psychopharmacology (Berl)
A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder
Int Clin Psychopharmacol
Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study
J Clin Psychopharm
Mirtazapine compared with paroxetine in major depression
J Clin Psychiatry
Mirtazapine orally disintegrating tablets versus venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder
J Clin Psychopharmacol
A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression
J Clin Psychiatry
A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder
J Clin Psychiatry
Citalopram and fluoxetine in major depression: comparison of two clinical trials in a psychiatrist setting and in general practice
Clin Drug Investigation
A comparative study for the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients
Curr Med Res Opin
Cited by (1353)
Predictive modeling of antidepressant efficacy based on cognitive neuropsychological theory
2024, Journal of Affective DisordersRapid response to antidepressants and correlation with response and remission after acute treatment
2024, Journal of Affective Disorders ReportsSerotonin is a common thread linking different classes of antidepressants
2023, Cell Chemical BiologyThe impact of antidepressants on human neurodevelopment: Brain organoids as experimental tools
2023, Seminars in Cell and Developmental Biology